Recombinant antibodies (rAbs) can be manufactured using synthetic genes expressed in an in vitro mammalian cell line. This is a biologically and chemically defined animal-free system unlike traditional hybridoma based technologies. This approach to the manufacture of antibodies has a number of inherent advantages that are outlined below.
At Absolute Antibody our recombinant antibodies are expressed in a chemically defined serum-free mammalian expression system. This eliminates contamination from serum components, such as bovine albumin and IgG, leading to a product with very high purity (>98%).
Reproducibility and control
Recombinant antibodies are biologically defined, with a known DNA and protein sequence, and as such it is ensured that the identical antibody is produced in each manufacturing batch. The possibility of genetic drift associated with hybridoma-based systems is removed completely and recombinant antibodies lack variability due to additional light chains that are often present in hybridomas. In addition, the manufacturing process is chemically defined, giving high purity and ultra-low batch-to-batch variability.
Decreased production time
At Absolute Antibody we have developed a high-yielding mammalian expression system that enables production of large quantities of recombinant antibody in a short-time period.
Unlike hybridoma-derived antibodies, recombinant antibodies can be reformatted to a different species, isotype or subtype. This opens up the possibility of switching antibodies into a more preferable format for in vitro or in vivo use. For further information on this service at Absolute Antibody click here.
Recombinant antibodies can be engineered at the genetic level enabling production of recombinant antibody fragments, e.g. Fab and Fab2, bispecific antibodies, site-specific conjugation of antibodies and a myriad of other possibilities that are not available with conventional antibody technologies. For further information on this service at Absolute Antibody click here.
Although the antibody may originate from the immunisation of an animal , our manufacturing process is entirely animal free. This alleviates animal welfare concerns associated with traditional monoclonal antibody manufacturing – specifically ascites production from hybridomas.